American Association for the Advancement of Science, Science Immunology, 48(5), 2020
DOI: 10.1126/sciimmunol.abd0110
Full text: Unavailable
Acalabrutinib targets activated BTK in macrophages and was associated with reduced inflammation and clinical improvement in COVID-19.